Capricor Q1 net loss $9.8M; HOPE-3 Cohort A fully enrolled for Q4 data

CAPRICOR THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.31 revenue$4,906,877

Net loss $9.8M ($0.31/share) vs $7.8M loss prior year; revenue $4.9M from Nippon Shinyaku milestone.
Phase 3 HOPE-3 Cohort A fully enrolled (61 patients); top-line results expected Q4 2024.
Positive Type-B CMC FDA meeting confirmed manufacturing comparability between facilities.
Received $10M milestone from Nippon Shinyaku; $90M pre-approval milestones remain possible.
Cash $39.9M stable; runway into Q1 2025, excluding additional milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

CAPRICOR THERAPEUTICS, INC. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-007958

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.